Navigation Links
New mouse model may lead to new therapies for degenerative diseases
Date:5/15/2011

Boston (May 16, 2011) Most degenerative diseases begin with a gradual loss of specific cell types that progresses, eventually leading to symptoms. For example, in type I diabetes, hyperglycemia commonly develops when approximately 80 percent of the beta cells in the pancreas are lost; in Parkinson's disease, motor dysfunction typically begins when neurons in a certain portion of the brain are decreased by 70 to 80 percent. Finding ways to stop early cell destruction is vital, but methods to do so have proven challenging because of limitations of models for early stages of cell loss.

A research team led by Albert Edge, Ph.D., principal investigator at the Massachusetts Eye and Ear Infirmary's Eaton-Peabody Laboratory and associate professor at Harvard Medical School, have engineered a new mouse that that can be used for research on degenerative disease. Their paper describing the findings, "Cre/lox mediated in vivo mosaic cell ablation to generate novel mouse models of degenerative disease," was published on May 16 in the Journal of Clinical Investigation.

The "Mos-iCsp3" mouse (for "mosaic inducible caspase 3 mouse") is engineered so that administration of a drug initiates destruction of cells in specifically designated tissues, explains Dr. Edge. Selection of the cell type to be killed is achieved by mating the Mos-iCsp3 mouse with a "Cre" mouse in which an enzyme called Cre recombinase is contained in selected tissues. Any cell that contains the enzyme begins to produce caspase 3. This protein, a so-called "cell death" protein, is subsequently kept in an inactive form until the mouse is treated with a drug that activates caspase 3. Upon treatment with the drug the selected cells die. Several hundred Cre mice exist and cover a broad array of cell types.

"The mouse provides a way to study degenerative diseases and a model organism in which to develop therapies for those diseases," Dr. Edge said. "We targeted inner ear hair cells, beta cells in the pancreas, and epidermal cells. We found that whereas the beta cells and skin cells showed some regeneration in response to cellular loss, inner ear hair cells were not capable of regeneration and thus hair cell death caused partial deafness. The mouse will expedite our efforts to replace inner ear cells lost in deafness."


'/>"/>

Contact: Vannessa Carrington
vannessa_carrington@meei.harvard.edu
617-573-3341
Massachusetts Eye and Ear Infirmary
Source:Eurekalert

Related biology news :

1. MARC travel awards announced for GSA Mouse Genetics Conference
2. Mutant mouse reveals new wrinkle in genetic code, say UCSF scientists
3. Freeway air bad for mouse brain
4. Nicotine does not promote lung cancer growth in mouse models
5. Study shows rapamycin reverses myocardial defects in mouse model of LEOPARD syndrome
6. Researchers describe first functioning lipidome of mouse macrophage
7. Researchers insert identification codes into mouse embryos
8. Mouse brain seen in sharpest detail ever
9. Exposure to low doses of BPA alters gene expression in the fetal mouse ovary
10. Scientists reprogram mouse fat cells into clinically useful stem cells
11. Mouse stem cell study offers new insights into body fat distribution
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2016)... --  The Weather Company , an IBM Business (NYSE: ... in which consumers will be able to interact with IBM ... voice or text and receive relevant information about the product ... have long sought an advertising solution that can create a ... and valuable; and can scale across millions of interactions and ...
(Date:6/1/2016)... , June 1, 2016 ... in Election Administration and Criminal Identification to Boost Global ... a recently released TechSci Research report, " Global Biometrics ... Region, Competition Forecast and Opportunities, 2011 - 2021", the ... billion by 2021, on account of growing security concerns ...
(Date:5/20/2016)...  VoiceIt is excited to announce its new ... By working together, VoiceIt and VoicePass will offer ... take slightly different approaches to voice biometrics, collaboration ... usability. Both ... "This marketing and technology partnership allows ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
(Date:6/23/2016)... -- The Biodesign Challenge (BDC), a university competition that asks ... systems and biotechnology, announced its winning teams at the ... York City . The teams, chosen ... MoMA,s Celeste Bartos Theater during the daylong summit. Keynote ... of architecture and design, and Suzanne Lee , ...
(Date:6/23/2016)... , June 23, 2016 Apellis Pharmaceuticals, ... 1 clinical trials of its complement C3 inhibitor, ... and multiple ascending dose studies designed to assess ... of subcutaneous injection in healthy adult volunteers. ... either as a single dose (ranging from 45 ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance Associates® ... provides a free webinar on Performing Quality Investigations: Getting to Root ... CT at no charge. , Incomplete investigations are still a major concern to ...
Breaking Biology Technology: